Pharmafile Logo

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis


You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of their knees, and if they were really unlucky, on their face? This child may have disliked going to the swimming pool and particularly suffered from flare-ups during cold winter or hot summer months. They might have tried to cover up their skin with long-sleeved clothing, or hide their face to avoid being stared at.

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more…

Read the full article: http://bit.ly/2I9EbcK

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Infographic: HCV EU

Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...

Taiwan: Exploring the Healthcare Opportunity in this Singular “Hybrid” Market

Published in eyeforpharma February 2016 by Rachel Howard

Gaining deeper insights within a hard to reach audience

Often a short research study isn’t sufficient to get the level of insights and understanding that you require, especially when working with a hard to reach target audience.It can also...

Living with RA Report

Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

Heather Desmet appointed new Head of Living With

We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.

Webinar Recording: The Art of Storytelling in Pharma Market Research

Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...